Menu
Lisa Harding, MD
Transforming Psychiatry with Compassion and Innovation
Dr. Lisa Harding is a board-certified psychiatrist and Yale graduate recognized as a global leader in treatment-resistant depression and interventional psychiatry. With over 6,000 advanced procedures performed, she combines cutting-edge expertise with a compassionate approach to care. Explore her full bio and download her CV to learn more about her journey and impact on the field.
Personalized Psychiatry, Powered by Innovation
As the medical director of Mood Institute, we specialize in advanced treatments for depression and mood disorders, including Spravato™, Ketamine, TMS, and comprehensive medication management. We deliver customized, multidisciplinary care supported by bilingual, culturally attuned services. Discover how our tools, technology, and expert team can help you heal—schedule a consult today.
Advancing Mental Health Through Research Excellence
Mood Institute offers unparalleled clinical trial expertise, specializing in treatment-resistant depression and next-generation therapies. Our AI-enhanced operations, rapid startup capability, and diverse patient engagement set us apart. Join groundbreaking studies or partner with us to shape the future of psychiatry—schedule a research consult today.
Inspiring Minds, Driving Innovation in Psychiatry
Dr. Harding is a sought-after speaker and consultant, sharing real-world insights into interventional psychiatry, clinical research, and health equity. With a history of global engagements, leadership roles, news and television appearance, she bridges clinical expertise and industry needs. Book Dr. Harding for keynote presentations, CME programs, or strategic consulting engagements.
Thought Leadership That Shapes Modern Psychiatry
Dr. Harding’s expertise is frequently featured in leading publications including Forbes, Medscape, and Psychiatric Times. Her contributions span clinical insights, ethical discussions, and innovations in mental health care. Explore her library of published work and see how her voice is influencing the next generation of psychiatric care.
About Dr. Lisa Harding
Lisa Harding, MD has completed over 4,000 interventional procedures, including Electroconvulsive Therapy (ECT), Repetitive Transcranial Magnetic Stimulation (rTMS), Intranasal Esketamine (Spravato), and Intravenous Ketamine. She played a critical role in operationalizing Esketamine administration at Yale, ensuring compliance with Risk Evaluation and Mitigation Strategy (REMS) guidelines after its FDA approval in 2019.
Recognized as one of the top intervention psychiatrists in Connecticut, Dr. Harding is sought after locally, nationally, and internationally as an expert in her field. She has addressed audiences nationally and worldwide, including in Saudi Arabia, Singapore, Australia, Italy, Romania, Brazil, Mexico, Guyana, and St. Lucia. She has held leadership roles in the American Psychiatric Association (APA) and served as Vice President of the American Society of Ketamine Physicians, Psychotherapists & Practitioners.
Congresso Brasileiro de Psiquiatria
Saudi Arabia
Main stage panel
Saudi Arabia
Main stage panel
Saudi Arabia Workshop
Activating Procedures in TRD Management
Saudi Arabia Workshop
Activating Procedures in TRD Management
AHEAD Specialty Care Forum 2024
Conference Host
AHEAD Specialty Care Forum 2024
Conference Host
Mexico City
CONCIENCIA 2024 CDMX
Mexico City
CONCIENCIA 2024 CDMX
Main Stage Forum
Discussing Treatment Resistant Depression
Clinical Practice
At Mood Institute, we prioritize individualized care. Our services encompass:
Interventional Psychiatry (Spravato™, Ketamine, TMS).
Rapid relief options for treatment-resistant depression, administered under professional supervision.
Medication Management
Ongoing evaluation of medication effectiveness to ensure optimal outcomes.
Clinical Research and Innovation (Clinical and AI Driven Applications)
The study identifies eight crucial domains where AI improves clinical prediction, notably in diagnosis, prognosis, and personalized medicine.
About Mood Institute
Mood Institute is a best-in-class psychiatric clinic specializing in advanced, cutting-edge treatments for depression and mood disorders, including Esketamine (Spravato™), Ketamine, TMS, and medication management. Known for its personalized, bilingual care, the clinic combines clinical excellence with innovative technology to support superior patient outcomes. It has been selected as a clinical trial site for a PCORI-funded study comparing IV ketamine to Esketamine and will host two additional Phase 3 trials over the next three years—solidifying its role as a national leader in treatment-resistant depression and interventional psychiatric research.